Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma
Immune checkpoint inhibitors (ICIs) have profoundly reshaped the treatment paradigm for
non-small cell lung cancer (NSCLC). Despite these advancements, primary and secondary …
non-small cell lung cancer (NSCLC). Despite these advancements, primary and secondary …
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
R Zheng, X Liu, Y Zhang, Y Liu, Y Wang… - Frontiers in …, 2024 - frontiersin.org
Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly
common in recent years. Despite advances in intensive treatment modalities including …
common in recent years. Despite advances in intensive treatment modalities including …
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
BL Rodriguez, J Huang, L Gibson, JJ Fradette… - Molecular Cancer …, 2024 - AACR
We recently reported that resistance to PD-1 blockade in a refractory lung cancer–derived
model involved increased collagen deposition and the collagen-binding inhibitory receptor …
model involved increased collagen deposition and the collagen-binding inhibitory receptor …
Blood Vitamin C Levels of Patients Receiving Immunotherapy and Relationship to Monocyte Subtype and Epigenetic Modification
B Topham, M de Vries, M Nonis, R van Berkel… - Epigenomes, 2024 - mdpi.com
The treatment of metastatic melanoma has been revolutionised by immunotherapy, yet a
significant number of patients do not respond, and many experience autoimmune adverse …
significant number of patients do not respond, and many experience autoimmune adverse …
[HTML][HTML] Single-cell RNA seq-derived signatures define response patterns to atezolizumab+ bevacizumab in advanced hepatocellular carcinoma
S Cappuyns, M Piqué-Gili… - Journal of …, 2024 - journal-of-hepatology.eu
Abstract Background & Aims The combination of atezolizumab and bevacizumab (atezo+
bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing …
bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing …
[HTML][HTML] Global research trends in immunotherapy for non-small cell lung cancer patients with KRAS mutations: a bibliometric analysis
H Shen, C Li - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Background Immunotherapy, frequently combined with conventional chemotherapy, is
crucial for treating NSCLC. Kirsten rat sarcoma virus (KRAS) is a poor prognostic factor in …
crucial for treating NSCLC. Kirsten rat sarcoma virus (KRAS) is a poor prognostic factor in …